Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.5425 -0.0342 (-5.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
33 34 Next >
Analyst Ratings for Ocugen
Via Benzinga
Ocugen Highlights Interim Data From Gene Therapy Study For Genetic Vision Loss Disorder
Via Benzinga
GETY Stock Alert: Trillium Capital Wants a Seat on Getty Images’ Board
Getty Images (GETY) stock is on the rise Friday as investors take note of Trillium Capital seeking a seat on the company's Board. 
Via InvestorPlace
SOFI Stock Pops as Bank Stocks Gain
SoFi Technologies (SOFI) stock is on the rise Friday as the company's shares rally alongside other shares in the financial sector. 
Via InvestorPlace
Why Are Bank Stocks JPM, WFC, PNC On The Move Today?
Bank stocks are on the move Friday after several big companies in the sector released positive earnings reports this morning. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Moving Today?
Ocugen (OCGN) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial. 
Via InvestorPlace
Why Ocugen Stock Eked Out a Win Today
The company is clearly progressing on several fronts with its pipeline programs. 
Via The Motley Fool
Ocugen (OCGN) Q4 2022 Earnings Call Transcript
OCGN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
More Likely to 5x First: Novavax vs. Ocugen
They skyrocketed before. It could happen again. 
Via The Motley Fool
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis 
From Ocugen
Via GlobeNewswire
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via GlobeNewswire
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
Ocugen has recently broadened its pipeline. 
Via The Motley Fool
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
From Ocugen
Via GlobeNewswire
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
From Ocugen
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire... 
Via Benzinga
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 42 companies hit new 52-week lows. 
Via Benzinga
7 Heavily Shorted Penny Stocks for Your Short-Squeeze Watch List
Here are seven heavily shorted penny stocks that can potentially witness a sharp reversal rally in the foreseeable future. 
Via InvestorPlace
Ocugen Appoints Quan A. Vu as Chief Business Officer
From Ocugen
Via GlobeNewswire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Two of these stocks have what it takes to rebound and deliver lasting gains. 
Via The Motley Fool
Why GeneDx Holdings Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket
Gainers Freightos Limited (NASDAQ: CRGO) shares rose 69.2% to $17.75 in pre-market trading. Freightos listed on the Nasdaq following merger with special purpose acquisition company, Gesher I... 
Via Benzinga
3 of the Fastest-Growing Stocks on the Planet in 2023
These hypergrowth stocks are expected to deliver up to 1,075% sales growth this year. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.